Home
/
Moleculin Biotech, Inc.
/
Financials
/
Quarterly
Moleculin Biotech, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Moleculin Biotech, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 13, 2025
Q2
2025
Jun 30, 2025
$0
Aug 12, 2025
Q1
2025
Mar 31, 2025
$0
May 13, 2025
Q3
2025
Sep 30, 2024
$0
Nov 13, 2025
Q2
2025
Jun 30, 2024
$0
Aug 12, 2025
Q1
2025
Mar 31, 2024
$0
May 13, 2025
Q3
2024
Sep 30, 2023
$0
Nov 8, 2024
Q2
2024
Jun 30, 2023
$0
Aug 13, 2024
Q1
2024
Mar 31, 2023
$0
May 10, 2024
Q3
2023
Sep 30, 2022
$0
Nov 13, 2023
Q2
2023
Jun 30, 2022
$0
Aug 10, 2023
Q1
2023
Mar 31, 2022
$0
May 10, 2023
Q3
2022
Sep 30, 2021
$0
Nov 10, 2022
Q2
2022
Jun 30, 2021
$0
Aug 12, 2022
Q1
2022
Mar 31, 2021
$0
May 11, 2022
Q3
2021
Sep 30, 2020
$0
Nov 10, 2021
Q2
2021
Jun 30, 2020
$0
Aug 11, 2021
Q1
2021
Mar 31, 2020
$0
May 12, 2021
Q3
2020
Sep 30, 2019
$0
Nov 12, 2020
Q2
2020
Jun 30, 2019
$0
Aug 12, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2018
Sep 30, 2018
$0
Nov 13, 2018
Q2
2018
Jun 30, 2018
$0
Aug 10, 2018
Q1
2018
Mar 31, 2018
$0
May 14, 2018
Q3
2018
Sep 30, 2017
$0
Nov 13, 2018
Q2
2018
Jun 30, 2017
$0
Aug 10, 2018
Q1
2018
Mar 31, 2017
$0
May 14, 2018
Q3
2017
Sep 30, 2016
$0
Nov 13, 2017
Q2
2017
Jun 30, 2016
$0
Aug 11, 2017
Q1
2017
Mar 31, 2016
$0
May 12, 2017
Q3
2016
Sep 30, 2015
$0
Nov 21, 2016
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($25.40M)
Nov 13, 2025
Q3
2025
Jun 30, 2025
($17.81M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($7.64M)
Aug 12, 2025
Q2
2025
Mar 31, 2025
($6.44M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($6.44M)
May 13, 2025
Q3
2025
Mar 31, 2025
($5.90M)
Nov 13, 2025
Q3
2025
Sep 30, 2024
($7.02M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($4.32M)
Aug 12, 2025
Q3
2025
Jun 30, 2024
($6.02M)
Nov 13, 2025
Q2
2025
Mar 31, 2024
($4.97M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($4.97M)
May 13, 2025
Q3
2025
Mar 31, 2024
($6.43M)
Nov 13, 2025
Q3
2024
Sep 30, 2023
($5.61M)
Nov 8, 2024
Q3
2024
Jun 30, 2023
($5.98M)
Nov 8, 2024
Q2
2024
Jun 30, 2023
($5.98M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($7.92M)
May 10, 2024
Q2
2024
Mar 31, 2023
($7.92M)
Aug 13, 2024
Q3
2024
Mar 31, 2023
($7.92M)
Nov 8, 2024
Q3
2023
Sep 30, 2022
($8.61M)
Nov 13, 2023
Q3
2023
Jun 30, 2022
($6.78M)
Nov 13, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($5.91M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($5.72M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($5.94M)
May 13, 2025
Q3
2025
Sep 30, 2024
($7.14M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($6.19M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($6.68M)
May 13, 2025
Q3
2024
Sep 30, 2023
($5.95M)
Nov 8, 2024
Q2
2024
Jun 30, 2023
($6.41M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($8.35M)
May 10, 2024
Q3
2023
Sep 30, 2022
($9.08M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($7.43M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($7.07M)
May 10, 2023
Q3
2022
Sep 30, 2021
($6.16M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($5.52M)
Aug 12, 2022
Q1
2022
Mar 31, 2021
($6.09M)
May 11, 2022
Q3
2021
Sep 30, 2020
($6.15M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($5.03M)
Aug 11, 2021
Q1
2021
Mar 31, 2020
($5.06M)
May 12, 2021
Q3
2020
Sep 30, 2019
($4.51M)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($3.63M)
Aug 12, 2020